Christian Smedberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christian Smedberg has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Johnny Steuer
Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Sjukhusbacken 10, S-11883 Stockholm, Sweden
3 shared publications- Christian Olsson
Department of Molecular Medicine and Surgery, Karolinska Institute
2 shared publications - Karin Leander
Karolinska Institutet
2 shared publications Rebecka Hultgren
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
2 shared publications- Rebecka Hultgren
Department of Molecular Medicine and Surgery, Karolinska Institutet , Stockholm
2 shared publications Andreas Öjersjö
Department of Vascular Surgery, Kalmar Hospital, Sweden (A.O.).
1 shared publication
Latest Publications
- 24 September 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
Paclitaxel-Coated Devices in Patients With Chronic Limb-Threatening Ischemia and Tissue Loss Undergoing Infrainguinal Endovascular Revascularization: Insights From the SWEDEPAD-1 Trial
BACKGROUND: Patients with chronic limb-threatening ischemia and tissue loss (Rutherford 5–6) are at high risk of major amputation. Drug-coated technologies are effective in coronary interventions, but their impact on limb outcomes in advanced ischemia remains uncertain. We evaluated whether drug-coated devices improve limb salvage in this high-risk population. METHODS: This post hoc subgroup analysis used data from SWEDEPAD-1 (Swedish Drug-Elution Trial in Peripheral Arterial Disease), a multicenter registry-based randomized controlled trial of endovascular treatment for infrainguinal arterial disease. Adults with chronic limb-threatening ischemia were randomized 1:1 to treatment with paclitaxel-coated or uncoated endovascular devices. Only patients with tissue loss (Rutherford 5 or 6) were included. The primary end point was time to ipsilateral major amputation. Secondary end points were target vessel reintervention and a composite of major amputation or target vessel reintervention. Outcomes were assessed at 3 months, 1 year, and 5 years using intention-to-treat analyses and adjusted Cox proportional hazards models. RESULTS: Among 1761 patients (median age, 77 years; 60.1% male; 58.4% diabetes), ipsilateral major amputation within 3 months was more frequent in the paclitaxel-coated group than in the uncoated group (10.4% versus 7.5%; adjusted hazard ratio, 1.43 [95% CI, 1.04–1.96]). Amputation rates were similar at 1 year (16.3% versus 14.6%) and remained comparable through 5 years. Target vessel reintervention at 1 year was lower with paclitaxel-coated devices (13.6% versus 18.0%; adjusted hazard ratio, 0.77 [95% CI, 0.61–0.97]), but this difference was attenuated when early limb loss was included in a composite end point. No significant between-group differences were observed at 5 years. CONCLUSIONS: In patients with chronic limb-threatening ischemia and tissue loss, paclitaxel-coated devices did not improve limb salvage and were associated with a higher early risk of major amputation. Although target vessel reintervention was reduced at 1 year, this apparent benefit was not maintained when accounting for the competing risk of limb loss in a composite end point. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02051088.
- 24 September 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
Paclitaxel-Coated Devices in Patients With Chronic Limb-Threatening Ischemia and Tissue Loss Undergoing Infrainguinal Endovascular Revascularization: Insights From the SWEDEPAD-1 Trial
BACKGROUND: Patients with chronic limb-threatening ischemia and tissue loss (Rutherford 5–6) are at high risk of major amputation. Drug-coated technologies are effective in coronary interventions, but their impact on limb outcomes in advanced ischemia remains uncertain. We evaluated whether drug-coated devices improve limb salvage in this high-risk population. METHODS: This post hoc subgroup analysis used data from SWEDEPAD-1 (Swedish Drug-Elution Trial in Peripheral Arterial Disease), a multicenter registry-based randomized controlled trial of endovascular treatment for infrainguinal arterial disease. Adults with chronic limb-threatening ischemia were randomized 1:1 to treatment with paclitaxel-coated or uncoated endovascular devices. Only patients with tissue loss (Rutherford 5 or 6) were included. The primary end point was time to ipsilateral major amputation. Secondary end points were target vessel reintervention and a composite of major amputation or target vessel reintervention. Outcomes were assessed at 3 months, 1 year, and 5 years using intention-to-treat analyses and adjusted Cox proportional hazards models. RESULTS: Among 1761 patients (median age, 77 years; 60.1% male; 58.4% diabetes), ipsilateral major amputation within 3 months was more frequent in the paclitaxel-coated group than in the uncoated group (10.4% versus 7.5%; adjusted hazard ratio, 1.43 [95% CI, 1.04–1.96]). Amputation rates were similar at 1 year (16.3% versus 14.6%) and remained comparable through 5 years. Target vessel reintervention at 1 year was lower with paclitaxel-coated devices (13.6% versus 18.0%; adjusted hazard ratio, 0.77 [95% CI, 0.61–0.97]), but this difference was attenuated when early limb loss was included in a composite end point. No significant between-group differences were observed at 5 years. CONCLUSIONS: In patients with chronic limb-threatening ischemia and tissue loss, paclitaxel-coated devices did not improve limb salvage and were associated with a higher early risk of major amputation. Although target vessel reintervention was reduced at 1 year, this apparent benefit was not maintained when accounting for the competing risk of limb loss in a composite end point. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02051088.
- Open Access
Primary Subclavian Venous Thrombosis - Multidisciplinary Collaboration Improves Early Identification and Frequency of Surgical Intervention
Primary subclavian venous thrombosis (PSVT) is a rare but potentially disabling condition caused by chronic compression of the subclavian vein at the thoracic outlet, typically affecting young individuals. Delayed diagnosis often leads to post-thrombotic syndrome (PTS) due to missed opportunities for early surgical intervention. In Stockholm, Sweden, a regional awareness and referral program initiated in 2013 significantly increased early detection and intervention rates. Between 2013 and 2024, 283 PSVT cases were identified, with incidence rising from 0.6 to 1.5 per 100,000/year, attributed to improved detection. Early surgical intervention rose from 66% to 83%, while PTS cases requiring delayed surgery dropped by 50%. These results underscore the benefit of structured regional programs.
Open AccessPrimary Subclavian Venous Thrombosis - Multidisciplinary Collaboration Improves Early Identification and Frequency of Surgical Intervention
Primary subclavian venous thrombosis (PSVT) is a rare but potentially disabling condition caused by chronic compression of the subclavian vein at the thoracic outlet, typically affecting young individuals. Delayed diagnosis often leads to post-thrombotic syndrome (PTS) due to missed opportunities for early surgical intervention. In Stockholm, Sweden, a regional awareness and referral program initiated in 2013 significantly increased early detection and intervention rates. Between 2013 and 2024, 283 PSVT cases were identified, with incidence rising from 0.6 to 1.5 per 100,000/year, attributed to improved detection. Early surgical intervention rose from 66% to 83%, while PTS cases requiring delayed surgery dropped by 50%. These results underscore the benefit of structured regional programs.
- Open Access
- 10 May 2024
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 106, 61-70
Acute Symptomatic Isolated Abdominal Aortic Dissection – Clinical Characteristics, Outcome, and Sex Differences
- 10 May 2024
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 106, 61-70
Open AccessAcute Symptomatic Isolated Abdominal Aortic Dissection – Clinical Characteristics, Outcome, and Sex Differences
- Open Access
- 13 March 2024
- Published by BMJ in Open Heart
- Vol. 11 (1) , e002595
Incidence, presentation and outcome of acute aortic dissection: results from a population-based study
Objectives To describe the incidence of acute aortic dissection in a clearly defined population, to assess onset symptoms and admission biochemical marker levels and to analyse variables potentially associated to mortality. Methods Medical records and CT angiograms of all patients hospitalised for acute aortic dissection in the Stockholm County during the 5-year period 2012–2016 were reviewed. The patients were followed until date of death or until 31 December 2020. The annual incidence was determined. Associations between clinical and biochemical variables and 30-day mortality, respectively, were analysed using multivariable logistic regression models. Results A total of 344 patients were included. The mean annual incidence of acute aortic dissection was 4.1 per 100 000. Median age was 67 years (range 24–91) and 34% (n=118) were women. Type A dissection was predominant; 220 patients (64%) had type A and 124 (36%) had type B. Painless dissection was more common in type A than in type B (18% vs 15%, p=0.003). Type A dissection patients also more commonly had elevated plasma troponin T (44% vs 21%, pConclusions Nearly two-thirds of acute aortic dissection patients had type A. Levels of troponin T and platelets, respectively, paired with presence or absence of typical symptoms may become useful adjuncts in risk stratification of patients with acute aortic dissection.
- 13 March 2024
- Published by BMJ in Open Heart
- Vol. 11 (1) , e002595
Open AccessIncidence, presentation and outcome of acute aortic dissection: results from a population-based study
Objectives To describe the incidence of acute aortic dissection in a clearly defined population, to assess onset symptoms and admission biochemical marker levels and to analyse variables potentially associated to mortality. Methods Medical records and CT angiograms of all patients hospitalised for acute aortic dissection in the Stockholm County during the 5-year period 2012–2016 were reviewed. The patients were followed until date of death or until 31 December 2020. The annual incidence was determined. Associations between clinical and biochemical variables and 30-day mortality, respectively, were analysed using multivariable logistic regression models. Results A total of 344 patients were included. The mean annual incidence of acute aortic dissection was 4.1 per 100 000. Median age was 67 years (range 24–91) and 34% (n=118) were women. Type A dissection was predominant; 220 patients (64%) had type A and 124 (36%) had type B. Painless dissection was more common in type A than in type B (18% vs 15%, p=0.003). Type A dissection patients also more commonly had elevated plasma troponin T (44% vs 21%, pConclusions Nearly two-thirds of acute aortic dissection patients had type A. Levels of troponin T and platelets, respectively, paired with presence or absence of typical symptoms may become useful adjuncts in risk stratification of patients with acute aortic dissection.
- Open Access
- 17 November 2022
- Published by BMJ in Open Heart
- Vol. 9 (2) , e002082
Pharmacological treatment in patients with aortic dissection
Objectives To describe medical management in aortic dissection (AD) and to analyse the possible associations between antihypertensive, antithrombotic, anticoagulant and statin agents, respectively, and long-term survival. Methods From Swedish medical registers, all patients diagnosed with AD in 2006–2015 were identified. Filled prescriptions prior to admission and within 1 year from discharge in patients discharged and alive at 30 days were registered. Associations between pharmacological treatment and long-term survival were analysed using Cox proportional hazards models. Results Of 3951 patients hospitalised with acute AD, 3046 (77%) were discharged and alive at 30 days. In hospitalised patients, mean age was 66 years (SD 13), and 36% (n=1098) were women. Within 1 year from discharge, 96% (n=2939) had at least one antihypertensive drug. Beta blocker was the most commonly used drug type (90%, n=2741). Statin treatment (47%, n=1418) was associated with higher long-term survival; HR 0.74 (95% CI 0.63 to 0.87, pConclusions Statin treatment was associated with favourable long-term outcome in medically managed AD patients, whereas treatment with beta blocker was associated with higher survival only in surgically managed AD patients. Statin use as well as optimal antihypertensive therapy in the chronic stage of the disease need to be further analysed, preferably in randomised controlled trials.
- 17 November 2022
- Published by BMJ in Open Heart
- Vol. 9 (2) , e002082
Open AccessPharmacological treatment in patients with aortic dissection
Objectives To describe medical management in aortic dissection (AD) and to analyse the possible associations between antihypertensive, antithrombotic, anticoagulant and statin agents, respectively, and long-term survival. Methods From Swedish medical registers, all patients diagnosed with AD in 2006–2015 were identified. Filled prescriptions prior to admission and within 1 year from discharge in patients discharged and alive at 30 days were registered. Associations between pharmacological treatment and long-term survival were analysed using Cox proportional hazards models. Results Of 3951 patients hospitalised with acute AD, 3046 (77%) were discharged and alive at 30 days. In hospitalised patients, mean age was 66 years (SD 13), and 36% (n=1098) were women. Within 1 year from discharge, 96% (n=2939) had at least one antihypertensive drug. Beta blocker was the most commonly used drug type (90%, n=2741). Statin treatment (47%, n=1418) was associated with higher long-term survival; HR 0.74 (95% CI 0.63 to 0.87, pConclusions Statin treatment was associated with favourable long-term outcome in medically managed AD patients, whereas treatment with beta blocker was associated with higher survival only in surgically managed AD patients. Statin use as well as optimal antihypertensive therapy in the chronic stage of the disease need to be further analysed, preferably in randomised controlled trials.
- Open Access
- 1 November 2021
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 62 (5) , 694
Massive Endoleak From Retro-Aortic Left Renal Vein Fistula
- 1 November 2021
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 62 (5) , 694
Open AccessMassive Endoleak From Retro-Aortic Left Renal Vein Fistula
- Open Access
- 19 June 2020
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (26) , 2430-2438
Sex differences and temporal trends in aortic dissection: a population-based study of incidence, treatment strategies, and outcome in Swedish patients during 15 years
As large population-based studies of aortic dissection are lacking, the incidence numbers and knowledge about time-trends and sex differences are uncertain. The objective was to describe incidence, temporal trends and outcome of aortic dissection with particular emphasis on sex differences. During the study period 2002–2016, 8057 patients in Sweden were diagnosed with aortic dissection, identified from the National Patient Register and the Cause of Death Register. A total of 5757 (71%) patients were hospitalized, whereas 2300 (29%) patients were deceased without concurrent hospital stay. The annual incidence was 7.2 per 100 000 (9.1 in men and 5.4 in women), decreasing over time in men (P = 0.005). Mean age in the hospitalized patients was 68 years (SD 13), 2080 (36%) were women. Within the first 14 days after onset, 1807 patients (32%) underwent surgical repair. The proportion of surgically treated increased from the 5-year period 2002–2006 to 2012–2016 [27% vs. 35%, odds ratio (OR) 1.61, 95% confidence interval (CI) 1.39–1.86; P < 0.001]. In hospitalized patients, 30-day mortality decreased between the same periods (26% vs. 21%, OR 0.68, 95% CI 0.59–0.80; P < 0.001). Long-term mortality decreased as well (hazard ratio 0.74, 95% CI 0.67–0.82; P < 0.001). Women had higher 30-day mortality than men after acute repair, a sex difference that remained after age adjustment (17% vs. 12%, OR 1.38, 95% CI 1.04–1.82; P = 0.006). This population-based study detected a higher incidence of aortic dissection than prior reports, but a decreasing incidence in men. Surgical therapy was increasingly used and with more favourable outcome but was less frequently offered to elderly patients. The sustained sex differences regarding both incidence and outcome require further attention.
- 19 June 2020
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (26) , 2430-2438
Open AccessSex differences and temporal trends in aortic dissection: a population-based study of incidence, treatment strategies, and outcome in Swedish patients during 15 years
As large population-based studies of aortic dissection are lacking, the incidence numbers and knowledge about time-trends and sex differences are uncertain. The objective was to describe incidence, temporal trends and outcome of aortic dissection with particular emphasis on sex differences. During the study period 2002–2016, 8057 patients in Sweden were diagnosed with aortic dissection, identified from the National Patient Register and the Cause of Death Register. A total of 5757 (71%) patients were hospitalized, whereas 2300 (29%) patients were deceased without concurrent hospital stay. The annual incidence was 7.2 per 100 000 (9.1 in men and 5.4 in women), decreasing over time in men (P = 0.005). Mean age in the hospitalized patients was 68 years (SD 13), 2080 (36%) were women. Within the first 14 days after onset, 1807 patients (32%) underwent surgical repair. The proportion of surgically treated increased from the 5-year period 2002–2006 to 2012–2016 [27% vs. 35%, odds ratio (OR) 1.61, 95% confidence interval (CI) 1.39–1.86; P < 0.001]. In hospitalized patients, 30-day mortality decreased between the same periods (26% vs. 21%, OR 0.68, 95% CI 0.59–0.80; P < 0.001). Long-term mortality decreased as well (hazard ratio 0.74, 95% CI 0.67–0.82; P < 0.001). Women had higher 30-day mortality than men after acute repair, a sex difference that remained after age adjustment (17% vs. 12%, OR 1.38, 95% CI 1.04–1.82; P = 0.006). This population-based study detected a higher incidence of aortic dissection than prior reports, but a decreasing incidence in men. Surgical therapy was increasingly used and with more favourable outcome but was less frequently offered to elderly patients. The sustained sex differences regarding both incidence and outcome require further attention.
- 1 September 2018
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 56 (3) , 349-355
Temporal and Morphological Patterns Predict Outcome of Endovascular Repair in Acute Complicated Type B Aortic Dissection
- 1 September 2018
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 56 (3) , 349-355
Temporal and Morphological Patterns Predict Outcome of Endovascular Repair in Acute Complicated Type B Aortic Dissection